首页 工具
登录
购物车
Alvespimycin hydrochloride

Alvespimycin hydrochloride

产品编号 T6297   CAS 467214-21-7
别名: BMS 826476, NSC 707545, 阿螺旋霉素盐酸盐, KOS-1022, 17-DMAG hydrochloride, Alvespimycin (17-DMAG) HCl

Alvespimycin hydrochloride (BMS 826476) 是一种Hsp90抑制剂,结合到 Hsp90,EC50为 62±29 nM。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Alvespimycin hydrochloride Chemical Structure
Alvespimycin hydrochloride, CAS 467214-21-7
规格 价格/CNY 货期 数量
5 mg ¥ 255 现货
10 mg ¥ 417 现货
25 mg ¥ 840 现货
50 mg ¥ 1,294 现货
1 mL * 10 mM (in DMSO) ¥ 460 现货
其他形式的 Alvespimycin hydrochloride:
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
重组蛋白限时优惠
产品目录号及名称: Alvespimycin hydrochloride (T6297)
点击图片重新获取验证码
选择批次  
纯度: 99.94%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Alvespimycin hydrochloride (BMS 826476) is a potent HSP90 inhibitor with IC50 of 62 nM. Phase 2.
靶点活性 HSP90:62 nM
体外活性 17-DMAG displays ~2 times potency against human Hsp90 than 17-AAG, with IC50 of 62 nM versus 119 nM. In SKBR3 and SKOV3 cells which over-express Hsp90 client protein Her2, 17-DMAG causes down-regulation of Her2 with EC50 of 8 nM and 46 nM, respectively, as well as induction of Hsp70 with EC50 of 4 nM and 14 nM, respectively, leading to significant cytotoxicity with GI50 of 29 nM and 32 nM, respectively, consistent with Hsp90 inhibition. [1] 17-DMAG in combination with vorinostat synergistically induces apoptosis of the cultured MCL cells as well as primary MCL cells, more potently than either agent alone, by markedly attenuating the levels of cyclin D1 and CDK4, as well as of c-Myc, c-RAF and Akt. [3] In contrast to 17-AAG which is only active for IKKβ in chronic lymphocytic leukemia (CLL) cells, 17-DMAG treatment effectively leads to depletion of the Hsp90 client protein, resulting in diminished NF-κB p50/p65 DNA binding, decreased NF-κB target gene transcription, and caspase-dependent apoptosis. By targeting the NF-κB family, 17-DMAG selectively mediates dose- and time-dependent cytotoxicity against CLL cells, but not normal T cells or NK cells important for immune surveillance. [5]
体内活性 17-DMAG treatment at 5 mg/kg or 25 mg/kg thrice per week significantly reduces tumor growth of TMK-1 xenografts, by significantly reducing vessel area and numbers of proliferating tumor cells in sections. [2] Consistent the inhibition of FAK signaling in vivo, 17-DMAG treatment at 25 mg/kg three times a week significantly suppresses tumor growth, and metastasis of ME180 and SiHa xenografts in mice. [4] Administration of 17-DMAG at 10 mg/kg for 16 days significantly decreases the white blood cell count and prolongs the survival in a TCL1-SCID transplant mouse model. [5]
激酶实验 Fluorescence polarization (FP)-based competition binding assay: This assay utilizes a boron difluoride dipyrromethene (BODIPY) labeled geldanamycin analogue (BODIPY-AG) as a probe and measured fluorescence polarization upon binding of the probe to a protein. Native human Hsp90 protein (α + β isoforms) is isolated from HeLa cells. BODIPY-AG solution is freshly prepared in FP assay buffer (20 mM HEPES-KOH, pH 7.3, 1.0 mM EDTA, 100 mM KCl, 5.0 mM MgCl2, 0.01% NP-40, 0.1 mg/mL fresh bovine γ-globulin (BGG), 1.0 mM fresh DTT, and protease inhibitor from stock solution in DMSO. Competition curves are obtained by mixing 10 μL each of a solution containing BODIPY-AG and Hsp90, and a serial dilution of 17-DMAG freshly prepared in FP assay buffer from stock solution in DMSO. Final concentrations are 10 nM BODIPY-AG, 40 or 60 nM Hsp90, varying concentration of 17-DMAG (0.10 nM-10 μM), and ≤0.25% DMSO in a 384-well microplate. After 3 hours incubation at 30 °C, fluorescence anisotropy (γEx = 485 nm, γEm = 535 nm) is measured on an EnVision 2100 multilabel plate reader. IC50 value of 17-DMAG is obtained from the competition curves.
细胞实验 Cells are exposed to various concentrations of 17-DMAG for 24, or 48 hours. For the assessment of cytotoxicity, MTT reagent is then added, and plates are incubated for an additional 24 hours before spectrophotometric measurement. Apoptosis is determined by staining with annexin V-fluorescein isothiocyanate and propidium iodide (PI).(Only for Reference)
别名 BMS 826476, NSC 707545, 阿螺旋霉素盐酸盐, KOS-1022, 17-DMAG hydrochloride, Alvespimycin (17-DMAG) HCl
分子量 653.21
分子式 C32H48N4O8·HCl
CAS No. 467214-21-7

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

Ethanol: 6.5 mg/mL (10 mM)

DMSO: 19.6 mg/mL (30 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 1.5309 mL 7.6545 mL 15.309 mL 38.2725 mL
5 mM 0.3062 mL 1.5309 mL 3.0618 mL 7.6545 mL
10 mM 0.1531 mL 0.7655 mL 1.5309 mL 3.8273 mL
DMSO 20 mM 0.0765 mL 0.3827 mL 0.7655 mL 1.9136 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Ge J, et al. J Med Chem, 2006, 49(15), 4606-4615. 2. Lang SA, et al. Mol Cancer Ther, 2007, 6(3), 1123-1132. 3. Rao R, et al. Cancer Biol Ther, 2009, 8(13), 1273-1280. 4. Schwock J, et al. Cancer Res, 2009, 69(11), 4750-4759. 5. Hertlein E, et al. Blood, 2010, 116(1), 45-53. 6. Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel). 2016 Aug 24;8(9). pii: E77.
Furanodienone Isoliquiritigenin Asiatic acid MDK83190 Trolox 4-Methyldaphnetin Iberdomide Doxorubicin hydrochloride

相关化合物库

该产品包含在如下化合物库中:
抑制剂库 抗癌活性化合物库 抗癌药物库 抗癌临床化合物库 药物功能重定位化合物库 经典已知活性库 细胞凋亡化合物库 抗癌化合物库 临床期小分子药物库 细胞骨架化合物库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Alvespimycin hydrochloride 467214-21-7 Apoptosis Cytoskeletal Signaling Metabolism HSP KOS 1022 inhibit Inhibitor 17-DMAG BMS 826476 NSC 707545 NSC-707545 阿螺旋霉素盐酸盐 KOS-1022 Alvespimycin 17-DMAG Hydrochloride Alvespimycin Hydrochloride Heat shock proteins 17-DMAG hydrochloride KOS1022 BMS826476 BMS-826476 Alvespimycin (17-DMAG) HCl NSC707545 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼